Meanwhile, some remaining parts of the international consensus, especially the recent WHO molecular classification for gliomas, are planned to be established in the coming years when almost all our CNS malignancy care accounts are equipped with such molecular testing set-ups (1p/19q co-deletion, MGMT promoter methylation, IDH1/2 mutation). This evidence concerns the gene IDH1 and central nervous system cancer.